This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. — Barrons.com

By Mackenzie TatananniAs shares of Myriad Genetics show no signs of returning to their peak from over two decades ago, one firm double-downgraded the already depressed stock, saying the company's latest earnings cast doubt on the biotech company's ability to become consistently profitable.Piper San…